KPV

KPV (lysine-proline-valine) is a tripeptide corresponding to the C-terminal sequence (residues 11-13) of alpha-melanocyte-stimulating hormone (alpha-MSH). Unlike the full alpha-MSH molecule, KPV does not appear to activate classical melanocortin receptors or raise intracellular cAMP, yet it retains anti-inflammatory activity, making it a focus of research into receptor-independent immune modulation. Most of the evidence for KPV comes from preclinical work: cell-culture experiments and rodent models of inflammatory bowel disease (colitis), contact dermatitis, and systemic inflammation. It is studied across multiple routes (oral, topical, and subcutaneous) because different formulations target different tissues - the gut, the skin, or systemic inflammation. It is important to be clear about the evidence ceiling: there are no published controlled human efficacy trials demonstrating clinical benefit, and no regulatory approval of KPV as a drug. Marketed dosing protocols are derived from animal studies and community/vendor anecdote, not from human trials. KPV is sold and discussed strictly as a research compound, not as a treatment for any condition.